Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$9.89 - $13.64 $2,304 - $3,178
-233 Reduced 14.51%
1,373 $18.7 Million
Q4 2023

Feb 14, 2024

BUY
$8.57 - $11.06 $13,763 - $17,762
1,606 New
1,606 $17.6 Million

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $293M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Point72 Asia (Singapore) Pte. Ltd. Portfolio

Follow Point72 Asia (Singapore) Pte. Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asia (Singapore) Pte. Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asia (Singapore) Pte. Ltd. with notifications on news.